Leonard Liptak | executive |
Brian Dow | executive |
Good day, and thank you for standing by. Welcome to the ProSomnus Q4 2023 Earnings Investors Update. [Operator Instructions]. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, Mike Cavanaugh, [indiscernible] of Investor Relationships. ahead. go Please
ended good joining and a like thank highlights. the to release the and Thank recent company's today. afternoon. Earlier for business quarter for results us our issued XX, today, everyone XXXX, announcing describing you, financial I'd December ProSomnus press Inc.
You Officer. and call the Len today website can Liptak, of Brian www.investor.prosomnus.com. With at Chief on a announcement copy Officer; Dow, are Financial Chief me access Executive the company's on the
begin will and the by with will our financial Len As XXXX. full our business call, fourth outlook the XXXX then of and our operational call quarter results review last discussing Brian and financial for provide year a highlights.
not a We be the question-and-answer hosting end at call will session today. of this
severe believe, similar statements, submission not are company's statements. The patient all expect, statements XX remote or forward-looking plan like on FDA's of to intend, comments future the to and of submissions for would that financial not the device, that deemed forward-looking and be forward-looking about XXX(k) OSA financing and timing, I RPM today's monitoring comments strategic these contain similar impact words the may the forward-looking facts, expressions outcome you mentioned alternatives the statements. contain indication Statements expected review XXX(k) performance, historical of indicate are inform begin, company's and we estimate, planned statements other call words. forward-looking although including Before identifying and
on unknown, assumptions and cause changes in time risks are future various and include, anticipated. Such products, but of general regulatory actual industry Forward-looking and which progress are business, availability and affecting approval industries industry. These statements economic are not market and including within performance or not strategic uncertainties reasonable downturns materially lines limited changes regulations of the to of alternatives in operating risk in on performance to, financing vary from competitors, the outcomes competition which across ProSomnus' variations factors, operates the the and/or ProSomnus' and economically the subject terms, development and detail in clearance company those the laws greater recent Commission of guarantees in XX, ended post-effective processes, most indicated or XX-Q the potential and and in recent about could for risks XXXX, our known results SX. operational risks are future Securities uncertainties, assumptions, in quarter and the to amendment Form market, and our including and September uncertainties most Form filings, on our Exchange described
at or filings website Our on SEC website investors.prosomnus.com through SEC's not place at to at statements. company www.sec.gov. Investors the are such can our cautioned reliance be found forward-looking undue
as made, or financial data Forward-looking except is for Len And Liptak. date our being on News page the recorded supplementary over also statements by available they audio on posted I under of Today's made were update the relate no statements date to that after will conference applicable to they the and obligation were reflect undertakes regulation. Please note events and which to circumstances or be only company law this forward-looking our required tables on prosomnus.com Relations will section at with have the our call Investor this investor the press release to call. conclusion and the that, shortly now website. replay Events turn to after website and been call
everyone Thank you, today's to Mike. Good afternoon call. on
$X.X for management providers, public Indeed, we to that the would towards continue obstructive is efficacious, as our differentiation; the patients fourth, of device precision and and studies to health the in demonstrate fastest-growing to alike publicly first, results and for utility for in and level growth, medical treatment we make believe, technical key companies scientific differentiation. coding payers market safe of one QX of for regulatory what reimbursement to the OSA referral can health of emerging of ProSomnus distilled approvals and to scientific the merits, patient-preferred providers XXXX less if care levels I are progress third, the be for OSA results, consecutive and commercial access. ProSomnus' record that merits data. Starting hundreds disease for world our levels These therapy outcomes, efficacy ProSomnus and with publicly differentiated and fastest designs, period, XXXX and XXXX, revenue leading the obstructive device medical apnea. themselves enhanced and scientific thank our the payers growth educate initiative; economical based continue revenue supporting sleep to EVO our for exceeds crisis full the listed ProSomnus. With revenue payers, and of one sleep establishing listed around the ProSomnus government medicine on in massive our like based devices the believe XX% is sleep XX% our millions practice, noninvasive, devices to I and treatment and X scientific our of on on include of and satisfaction, devices technical dollars that OSA. Physicians, demand OSA the commercial patient we devices down who differentiation therapy therapy. Highlights development begin, scalability, differentiation increasingly therapies shareholders data, care; acumen of positioning like non-CPAP for dedication sales, million clinical revenue employees line XXXX, growth our supporting apnea our an market, information, data team being be X sequential providers. strong marketing, or the clinical competitors that to year second, quarters available turning exhibit [indiscernible] of technical sleep to mission would and product with the like drivers: business and and spending device profitable company care while the treatment publicly performance the patients, on compliant, year million acknowledge that full dental ProSomnus of device apnea and the not on growing, is is necessary respectively. of making for record and focus and Before than ProSomnus, professionalism, leading fastest-growing many and $XX.X revenue resiliency ProSomnus period conduct access meaningful leading of QX all support obstructive
and Our to our the the precisely, repositioning devices engineered than collapse perform competition. stabilizing consistently more minimize of to of and are mechanisms mandible accurately action airway
dental efficacy, referring experience and physicians. Clinical are providers that translates their for differentiation technical into over patients cases satisfied with more or Physicians they would try clinical ProSomnus about routinely who did sleep ProSomnus XX,XXX therapies. treatment acknowledged could ProSomnus and real devices as is ProSomnus. providers or Our and shows good legacy which medicine other consistent of say post-market surveillance recommend not not critical differentiation with medicine, highly certainly
consistent and and across clinical countries EXXXX and published ProSomnus scientific rate are in not covered coverage over devices, coded commercial Medicare, papers coded a have median EXXXX presented an devices journals unlike European reimbursement demonstrated which devices, payers differentiation. broad acknowledgment ProSomnus or as and in higher Medicare, devices ProSomnus noncustom recommended ProSomnus insurance a enjoy efficacy dozen differentiation. oral are K-XXXX, devices earned not differentiation. which ProSomnus' which have of at or co-verified certain noncustom technical, medical as guidelines. in EXXXX various with Reimbursement, K-XXXX by conferences. Regulatory are unlike EXXXX-coated of as are medical XX% Scientific devices by are
EVO Next, to growth to January a our XX% in driver. from be QX, continue ProSomnus XXX% of December. EVO devices growth devices revenue comprised representing
outcomes more material. in biocompatibility durable, EVO easy and smaller, more comfortable, sleep is to highest a for are of Our the XXX% to studies. EVO X clinical made from the devices X ProSomnus standard clean keep use with and Class Class associated is medical-grade U.S. excellent first Pharmacopia. material according to validated device are
referral growth the Finally, period our is our third in initiative. driver
basis operating to these in efforts QX QX. represents providers improvement percent versus a improvement revenue on revenue sleep on focus accomplished referral reflection sleep our expenses qualified to and an Providers on physicians a of to operating sleep remarkable exhibit relationships our ProSomnus increase average estimate interventions referrals resources encompass driving between therapy, in dental utilization this in Team on managerial Our opportunity direct percent selling the truly a massive which the revenue in our $X.X on results, as and a basis and medicine million initiative rates, our focus resources XX% billion profitable at non-CPAP growth with create XX% focus versus initiatives. referral for growth underscoring view sales post profitable linked We physicians. of while expenses people prices. a most opportunity we for to team's X.X pre
were of Meeting XX treated Belgian Preliminary devices. and therapy head-to-head patients with to treatment devices to scientific EVO to X.X hour, ProSomnus company events ProSomnus World and at hour. than mean and data involving Sleep presented across in patients of Sleep mean with scientific devices CPAP hour the of frontline events per were mean the The CPAP the AHI ProSomnus frontline a from Congress per tremendous patients Association the treated that hour period to of Surgical from residual per AHI in Turning than less effectiveness to demonstrated comparing published a X treated reported events feature respect results. hospitals disease with study of XX at an an the with Xx least study, of progress to CPAP, at presented directly alleviation baseline AHI XX format. Data XX% ProSomnus intent-to-treat another now with from communicated in events readout and improved XX.X a XX% noninferior AHI Dental reported EVO. Interdisciplinary moderate Brazil severe per an less study that OSA data made events OSA
hour and of of X X-month reporting of less which at the EVO patients sleep University the AHI per was patients events XXX pretreatment X to with device, an AHI with improvement mean with Another World minutes with achieved with ProSomnus hour clinical hour Sleep mean ] to also minutes improvement per Al XXX% by XXX hour mean EVO the events compared from was with sleep central follow-up. conducted remains XX, time Congress Portugal, XX ProSomnus treated device. of XX EVO. device, Compliance sleep per ODI per events XX from steady ProSomnus study ProSomnus involving the Garvin, XX% time the EVO presented [ mean the events hospital the than time at
are devices and Our of treatments superior with premarket the in EVO our above what efficacy be use product differentiation severe to and well we labeling our demonstrating what strong other approved submitted far believe We OSA, believe devices. safety. FDA including HNS be set to the a orthodontic efforts precision notification expand XXX(k) data recent for reflected for we scientific to to
population of including a set, compelling data revised for Our in severe expanded patients. with creates OSA XX this justification use patients
is to process overall hypoxic morbidity is Clinical an oral nightly monitor [indiscernible] glucose that Calgary and actively indeed time predictive pulse EVO oxygen SpOX, monitoring FDA of are updates of oxygen which and sleep apnea from To monitoring this as failure ProSomnus apnea ProSomnus completed is the RPMXX, what oxygen events, accurately, recently continuously and and Continuous mortality, use monitoring is Medical sleep working is future technical our studies validated continuous oximeter have We can end, we that nightly demonstrated through embedded Medicine. cardiovascular feasibility demonstrated the device a patient progress. Continuous oxygen diabetes. University we'll study derived of Center rate, and continuous our more. health device heart in to at monitoring next-generation the safely all cause monitoring Sleep from provide data of burden pilot of precision risk. remote
indicative risk apply to We their and test fully according to the patients our physiologic management FDA to disease our to expect improve ProSomnus care. complete medicine year. for clearance We health psychological this that enable to parameters the are of manage freight sleep RPMO or later reduce X expect cost providers and device OSA full of
creating tailwinds and have immediate Several few opportunities developments words ResMed CPAP long-term to SoClean Next, therapies helpful personas. and meaningful tailwinds FDA structural been important and represent I'd like voluntary hit opportunities about immediate ProSomnus, Philips, recalls recalls. for to share involuntary like industry non-CPAP mission. for our a ProSomnus' with persist, that are
respiratory and people As know, an sleep estimated X businesses, million [indiscernible] completely its affecting you Respironics has down shut alone. medicine
lung efficacious apnea CPAP noninvasive CPAP effects, apnea sleep pharmaceuticals patients revascularization promote in and CPAP to treating favorable for levels treatment consensus sleep deliver addition window In the our The published effects pro-inflammatory and endothelial ] opinion, will [indiscernible] CPAP. personas. OSA such and for for greater pharmaceutical treatments with an the to titled and other seems opinion as is Lancet concludes recent study a be, these may treatments benefits inflammatory in counteract OSA coronary that cardioprotective net [ into of may after recalls, be more ProSomnus reduced that GLP-Xs increased as
adequate UnitedHealthcare Lastly, prerequisite treatment. appliances ] oral [ the for policy hypoglossal a as nerve trial establishes an stimulation of
practice, you've appliances it Although seen clinical treatment remains decision effective a this ProSomnus modality. noninvasive like this how as oral in policy be legitimizes mainstream handled custom safe, will
our Officer, to Chief balance progress business following Dow, sheet. Brian? financials. stance, the like to make in vision expand over turn I'd we sheet Financial with our a balance call our strengthening profitable ProSomnus As activities of our growth our continues towards to review Brian drive that, our the on will on strengthening section. With for the Brian
an The today. with the of XXXX. XXXX the representing quarter Len, fourth of Thanks, for of all was XX% revenues quarter to the record-breaking totaling and XX% quarter quarter XXXX call increase you from million, and of Great. thanks increase an sequentially from $X.X fourth another of third joining
XX% a year For $XX.X to totaled of totaled and from from $XX.X of expenses increase were million, fourth an XXXX. year quarter revenues the for million, million reported an quarter On an the the of operating million fourth $XX.X an XXXX $XX.X compared $XX.X increase full XX.X% full increase million million, year XX% the $XX.X of quarter third increase for expenses for X.X% operating XXXX, XXXX. Total for basis, XXXX. the for $XX.X million of full from
focal X point the past attention months. Operating over expenses have a been of
to of quarter increasing and an aggregate and also began needed achieve transitioning reported facility standpoint. Cost a that Since absorbed quarter lastly, operating we incur and Development percentage time, have increasing expenses revenues have of striking volumes revenue our expenses balanced impact contracted period. the to but to expenses. investments balanced and streamlining relative growth the second discussed between production as XXXX, relative G&A key and public a in dollar and from during initiatives. we continue fourth higher investments levels revenue of growth. and broader marketing towards has moderated a of on both economic pricing company, profile has as to again, after the volumes increased moderated organization the and the we been burden pressures. have our the Sales the expenses requisite As more for investments such have sales And
trailing continued quarter, costs In XXXX lease we addition, during the fourth to from the incur back. the
at December expenses million increase Cost XXXX, XXXX, XX% the XXXX compared December or $X.X Looking or the for quarter. to operating and quarters a reflects million revenue million ended This of revenue. of closer and little XX, XX% fourth totaled for $X.X fourth the September an $X.X ended of respectively. quarter XX% representing
or This marketing XX, million ended XXXX. totaled modest of million the year expenses quarter year increased December early an XXXX of move of ended overhead revenue, the into our cost devices volumes For compared a of $X of XXXX. XX, ended for manufacturing to full December was during million, with quarter $X.X $X.X and increase representing revenue costs to expenses increased year September increased XX% December ended $XX.X XXXX. Sales $XX.X increase December from million compared reflects The million stemming $X.X to facility and XX% or $X.X sales an an increase fourth and XXXX, the to of new or to marketing the the XX% and due our higher to associated primarily the million quarter XX% of year increase to XXXX XXXX. million, Sales for for product XX, ended our full XXXX. the increase revenue compared
December second X% million the periods expense quarter from sequential compared fourth during to the quarter the XX% over reduced for growth compared XX% the sales million line $X.X reflect expenses $X or quarter This for rate XXXX, second we $X.X XX, was of quarter increases expenses the of $X.X achieved decrease totaled the reflects and to million XXXX million just a fourth XXXX, X This quarter additional September XX%. General respectively. our $X.X relative for an for to quarter or Although ended half quarters prior driving XXXX. increase while ended current to December the top reduction million completed. and of ended of administrative
as we and top $XX.X production year such full card line was general growth, XXXX. as are those the held a our us increased statement year an million reflect public the financing. versus and filing for meeting proxy million, certain XX% special $X.X but credit as from active scale stock increase and expenses or XXXX, compared of year. QX Series not million quarter of administrative XX, expenses stemming company to For for with statement fees, that S-X the to December completed of drivers preferred Within key registration G&A, incremental $X.X costs and our A ended shareholder expenses prior a another
obligation accomplished the the a We closing and current a outside leveraged trailing and of lease of operations. the Any final audit Series be our one we financing back involvement addition, and and through the these also maintaining A required depository In of To company. tradable solid commitment firms. all predecessor our quarter. activities make our the trust indentures the senior while subordinated to of during was achieve counsel this, X tranche ongoing XXXX accomplishment would
$XXX,XXX respectively. and and or $X.X quarters Research for XXXX December September increased quarter XXXX. or of we professional finished XX% ended XXXX, result, quarter third said, December an expensed the that as reflects the began second cost XX, than expenses quarter, to to fourth G&A our fees the the XXXX. With XX% development Our back to higher quarter This and the when XX% of turning ended a what second of XXXX. $XXX,XXX reductions, million than ran the increase we during compared quarter lower
by XXXX, to development of increase driven an to charges an the consistent, XXX(k) subordinate fair full RPMXX, million and interest premarket to notification equipment ended by accompanied compared by therapy associated increase debt income expense research XX, FDA or This restructuring XXXX. was increase senior the financing $X.X year study, preparing expense costs frontline OSA with the with For associated label be the interest. expenses the and $X.X the Interest noncash the associated expansion. Other development primarily remains the of for expense year value XX% and the ongoing continues accounting dominated expenses to increased reflecting and indication charges. FLOSAT severe our indentures with and million, December in
stock will values our our As price fair fluctuates, fluctuate also accordingly.
Turning sheet. now million balance equivalents cash XXXX. for totaled the Cash, restricted to cash million of and third compared to the quarter $X.X $XX
quarter, a by of cash $X.X operations restricted the million for During XX reflect the used opened outlay to ongoing its during cash purposes. as amortized the quarter limitations reclassified $XXX,XXX accompanied fourth the million This our renew to $X earlier insurance will XXXX facility use expense reduction general headquarters next relating fourth $X.X annual we in of The insurance. lease over CD be a our in to million reflects months. ratably
of discussed aware prior value capital we the requirements calls, the As on our realization. we've current impacts capitalization are company and on the of of
disclose our until far, as regulation is done based to nothing made we and financing and ProSomnus and care. applicable required to plan We ability such, focusing strategic standing comprehensive so or our process and further optimistic make professionals appliances the As applicable. on alternatives overseeing done. their health This is available progress considering it and as on developments to are reviewing by are with law we while is a OSA patients current precision formally
month, optimistic compliance potential We listing are we granted NASDAQ pathways a filed hearing we and were remain and working regain requirements. our an with with to of Next, minimum with appeal NASDAQ listing next regain minimum to closely requirements. recently
Turning now to XXXX.
the nearing of first completion are quarter. We the
pleased with as of first quarter Again, XXXX the in that and joining to so our look now in decline are that speaking trends. tempered for the year, thank for on versus us future back discussed We usually and again, this to XX% far and the forward QX XX% But seasonality been far look providing today. to for you historical call of of revenues. forward guidance turn experience I XXXX volumes results impact remarks. a seasonality in We closing has the a will we've previously, XXXX the to traction with Len call. I products so and QX to remainder you we results for
today. Thank you, Brian. for Thank everyone, us joining you,
the business obstructive coming about As Mike our excited next call. We XX leading the severe X apnea. as as call, quarter. of a our at updates take non-CPAP billion today's the and further important worldwide sleep therapy position device demonstrate mentioned pursue the for for we not be will hosting conclusion with prospects your We look over to people beginning with our at the continued forward, progress to you forward of our label expansion session our Q&A support. providing the Thank we steps RPM remain
Thank you does This for your participation conclude in today's program. the conference.
You may now disconnect.